New insider activity at Alnylam Pharma ( (ALNY) ) has taken place on October 3, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a series of significant transactions, key executives at Alnylam Pharma have sold substantial shares of the company’s stock. EVP & CCO Tolga Tanguler sold 1,405 shares, amounting to $635,126. CEO Yvonne Greenstreet executed a larger sale of 8,924 shares, valued at $4,034,084. EVP Chief R&D Pushkal Garg parted with 2,937 shares, generating $1,327,674. CSO & EVP, Head of Research Fitzgerald Kevin Joseph sold 2,441 shares for $1,103,451. Lastly, EVP & CFO Jeffrey V. Poulton sold 3,821 shares, bringing in $1,727,283.
Recent Updates on ALNY stock
Alnylam Pharmaceuticals has recently provided updates on several clinical studies that could significantly influence its stock performance. The completion of a Phase 1 study for ALN-AGT01 RVR, which assessed its safety and pharmacokinetics, is a positive development that may boost investor confidence as it sets the stage for future trials. Additionally, the ongoing Phase 3 TRITON-CM study evaluating nucresiran for transthyretin amyloidosis with cardiomyopathy could impact the stock if the drug proves effective, potentially enhancing Alnylam’s market position in cardiovascular treatments. Furthermore, an open-label extension study on vutrisiran aims to assess its safety and efficacy for the same condition, which could further reinforce investor confidence in Alnylam’s pipeline. These clinical advancements highlight the company’s potential to strengthen its competitive stance in the pharmaceutical industry.
Spark’s Take on ALNY Stock
According to Spark, TipRanks’ AI Analyst, ALNY is a Neutral.
Alnylam Pharma’s overall stock score is primarily influenced by its strong earnings call performance, which highlights significant revenue growth and positive future guidance. However, financial performance remains a concern due to high leverage and negative profitability, which are significant risks. Technical analysis indicates strong momentum but warns of potential overbought conditions. Valuation metrics are weak due to negative earnings and lack of dividends.
To see Spark’s full report on ALNY stock, click here.
More about Alnylam Pharma
YTD Price Performance: 97.32%
Average Trading Volume: 1,154,318
Technical Sentiment Signal: Buy
Current Market Cap: $60.38B